tradingkey.logo

tradingkey.logo
怜玢


Alterity Therapeutics Ltd

ATHE
りォッチリストに远加
1.960USD
-0.135-6.44%
終倀 11-13 16:00ET
35.69M時䟡総額
損倱額盎近12ヶ月PER

Alterity Therapeutics Ltdに぀いお 䌁業名

Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.

Alterity Therapeutics Ltd プロフィヌル


䌁業コヌドATHE
䌚瀟名Alterity Therapeutics Ltd
䞊堎日Mar 28, 2000
最高経営責任者「CEO」Stamler (David A)
埓業員数9
蚌刞皮類Depository Receipt
決算期末Mar 28
本瀟所圚地Level 14, 350 Collins Street
郜垂MELBOURNE
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜Australia
郵䟿番号3000
電話番号61393494906
りェブサむトhttps://alteritytherapeutics.com/
䌁業コヌドATHE
䞊堎日Mar 28, 2000
最高経営責任者「CEO」Stamler (David A)

Alterity Therapeutics Ltdの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Peter Ashley Marks
Mr. Peter Ashley Marks
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Lawrence B. Gozlan
Mr. Lawrence B. Gozlan
Non-Executive Director
Non-Executive Director
--
--
Dr. David A. Stamler, M.D.
Dr. David A. Stamler, M.D.
Chief Executive Officer, Managing Director, Executive Director
Chief Executive Officer, Managing Director, Executive Director
--
--
Ms. Hannah Howlett
Ms. Hannah Howlett
Investor Relations
Investor Relations
--
--
Ms. Abby Macnish Niven
Ms. Abby Macnish Niven
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
--
--
Mr. Julian Barbaczy
Mr. Julian Barbaczy
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Ann Michelle Cunningham
Ms. Ann Michelle Cunningham
Non-Executive Independent Director
Non-Executive Independent Director
--
--
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Peter Ashley Marks
Mr. Peter Ashley Marks
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Lawrence B. Gozlan
Mr. Lawrence B. Gozlan
Non-Executive Director
Non-Executive Director
--
--
Dr. David A. Stamler, M.D.
Dr. David A. Stamler, M.D.
Chief Executive Officer, Managing Director, Executive Director
Chief Executive Officer, Managing Director, Executive Director
--
--
Ms. Hannah Howlett
Ms. Hannah Howlett
Investor Relations
Investor Relations
--
--
Ms. Abby Macnish Niven
Ms. Abby Macnish Niven
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
--
--
Mr. Julian Barbaczy
Mr. Julian Barbaczy
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--

よくある質問

Alterity Therapeutics Ltdの䞊䜍5名の株䞻は誰ですか


Alterity Therapeutics Ltdの䞊䜍5名の株䞻は以䞋のずおりです。Mr. Peter Ashley Marks

Alterity Therapeutics LtdATHEの株匏を保有しおいる機関の数はいく぀ですか


2026Q1時点で、Alterity Therapeutics Ltdの株匏を保有しおいる機関は32瀟あり、保有株匏の総垂堎䟡倀は玄327.31Kで、党䜓の1.81%を占めおいたす。2025Q4ず比范しお、機関の持ち株は-185355.00増加しおいたす。
tradingkey.logo
リスク告知圓瀟りェブサむト及びモバむルアプリは特定の投資商品に関する䞀般的な情報のみを提䟛しおおり、Finsightsは金融アドバむスや投資商品の掚奚を行うものではありたせん。本情報の提䟛をもっおFinsightsが投資助蚀を行っおいるず解釈されるこずはありたせん。
投資商品には元本割れを含む重倧なリスクが䌎い、党おの投資家に適するものではありたせん。なお、過去の運甚実瞟は将来の成果を保蚌するものではありたせん。
Finsightsは、第䞉者広告䞻たたは提携先が圓瀟りェブサむト・モバむルアプリ䞊に広告を掲茉するこずを蚱可する堎合があり、これら広告䞻から広告ぞの反応に基づく報酬を受けるこずがありたす。
© 著䜜暩: FINSIGHTS MEDIA PTE. LTD. 無断耇写・転茉を犁じたす。